Glycosmedia Weekly Diabetes News Update
View this email in your browser

Gold Sponsors:

Novo Nordisk

AstraZeneca

Boehringer Ingelheim

Silver Sponsors:

Abbott Diabetes Care

Ascensia Diabetes Care

Ericas

Glycosmedia Weekly Diabetes News - 03/11/2022

Suprachoroidal versus Intravitreal Triamcinolone Acetonide for the Treatment of Diabetic Macular Edema

SCTA is a safe and effective route for the treatment of DME, which has comparable effects to IVTA, and may even last longer (Clinical Ophthalmology)


Overestimation and underestimation of youths’ health-related quality of life are associated with youth and caregiver positive screens for depression

Caregivers often over- or underestimated their children’s QoL. Positive screens for depression among both youths and caregivers contributed to the observed differences between self- and caregiver-reported QoL (Diabetology & Metabolic Syndrome)


Exploratory study reveals far reaching systemic and cellular effects of verapamil treatment in subjects with type 1 diabetes

The current studies provide crucial mechanistic and clinical insight into the beneficial effects of verapamil in T1D (Nature)


The management of diabetic ketoacidosis in adults—An updated guideline from the Joint British Diabetes Society for Inpatient Care

This article summarises the Joint British Diabetes Societies for Inpatient Care guidelines on the management of ketoacidosis (Diabetic Medicine)


Effects of a Lifestyle Intervention to Prevent Deterioration in Glycemic Status Among South Asian Women With Recent Gestational Diabetes

This study found that a large proportion of women in South Asian urban settings developed dysglycemia soon after a GDM-affected pregnancy and that a lifestyle intervention, modified owing to the COVID-19 pandemic, did not prevent subsequent glycemic deterioration (JAMA)


The Gut Microbiome of Adults With Type 1 Diabetes and Its Association With the Host Glycemic Control

We identified a distinct gut microbial signature in adults with longstanding T1D and associations between microbial taxa, metabolic pathways, and glycemic control indices (Diabetes Care)


Real-world Evidence of Efficacy and Safety of SGLT2 Inhibitors as Adjunctive Therapy in Adults With Type 1 Diabetes: A European Two-Center Experience

Our real-world data on SGLT2i showed promising results in reductions in HbA1c, weight, and insulin requirements in type 1 diabetes. Benefits were more pronounced in individuals with higher baseline HbA1c and BMI. DKA remained a major concern, despite educational measures (Diabetes Care)


Serum bile acid response to oral glucose is attenuated in patients with early type 2 diabetes and correlates with 2h plasma glucose in individuals without diabetes

The serum BA response to a 75g oral glucose load is attenuated in patients with ‘early’ T2D, as is the secretion of FGF-19 and GLP-1, while in individuals without T2D it correlates with 2h plasma glucose levels. These observations support a role for BAs in the regulation of postprandial glucose metabolism (Diabetes, Obesity and Metabolism)


Share
Tweet
Forward
+1
Share
Please visit the Glycosmedia website for more features and information, including:

Journal Watch
Comment on recently published papers written by the medical editors of Glycosmedia.

Diabetes Updates
Updates written by Professor Steve Bain (Diabetologist) and Dr. Mark Freeman (Diabetologist).

Book and Product Reviews
A selection of book and product reviews written by the contributing editors of Glycosmedia.
The Glycosmedia website and newsletter has been made possible with funding support from our sponsors. None of our sponsors have control over the content of the website, newsletter, apps, Twitter feed or RSS newsfeed.

For information about sponsorship and advertising please contact our editor-in-chief Jim Young jim@glycosmedia.com

Glycosmedia complies with the HONcode standard for trustworthy health information: verify here.


Copyright © 2022 Glycosmedia Partnership

Our mailing address is:
Glycosmedia
9 Woodburn Drive
West Cross
Swansea, West Glamorgan SA3 5TZ
United Kingdom

Add us to your address book


unsubscribe from this list    update subscription preferences 

Email Marketing Powered by Mailchimp